These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 15956567)

  • 1. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.
    Bartosch B; Verney G; Dreux M; Donot P; Morice Y; Penin F; Pawlotsky JM; Lavillette D; Cosset FL
    J Virol; 2005 Jul; 79(13):8217-29. PubMed ID: 15956567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry.
    Callens N; Ciczora Y; Bartosch B; Vu-Dac N; Cosset FL; Pawlotsky JM; Penin F; Dubuisson J
    J Virol; 2005 Dec; 79(24):15331-41. PubMed ID: 16306604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.
    Anjum S; Wahid A; Afzal MS; Albecka A; Alsaleh K; Ahmad T; Baumert TF; Wychowski C; Qadri I; Penin F; Dubuisson J
    J Infect Dis; 2013 Dec; 208(11):1888-97. PubMed ID: 23908491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1.
    Lechner S; Rispeter K; Meisel H; Kraas W; Jung G; Roggendorf M; Zibert A
    Virology; 1998 Apr; 243(2):313-21. PubMed ID: 9568031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.
    Dreux M; Pietschmann T; Granier C; Voisset C; Ricard-Blum S; Mangeot PE; Keck Z; Foung S; Vu-Dac N; Dubuisson J; Bartenschlager R; Lavillette D; Cosset FL
    J Biol Chem; 2006 Jul; 281(27):18285-95. PubMed ID: 16675450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I.
    Voisset C; Callens N; Blanchard E; Op De Beeck A; Dubuisson J; Vu-Dac N
    J Biol Chem; 2005 Mar; 280(9):7793-9. PubMed ID: 15632171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus.
    Esumi M; Ahmed M; Zhou YH; Takahashi H; Shikata T
    Virology; 1998 Nov; 251(1):158-64. PubMed ID: 9813211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry.
    Voisset C; de Beeck AO; Horellou P; Dreux M; Gustot T; Duverlie G; Cosset FL; Vu-Dac N; Dubuisson J
    J Gen Virol; 2006 Sep; 87(Pt 9):2577-2581. PubMed ID: 16894196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation.
    Dao Thi VL; Dreux M; Cosset FL
    Expert Rev Mol Med; 2011 Apr; 13():e13. PubMed ID: 21489334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment.
    Zibert A; Schreier E; Roggendorf M
    Virology; 1995 Apr; 208(2):653-61. PubMed ID: 7538251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.
    Schvoerer E; Moenne-Loccoz R; Murray JM; Velay A; Turek M; Fofana I; Fafi-Kremer S; Erba AC; Habersetzer F; Doffoël M; Gut JP; Donlin MJ; Tavis JE; Zeisel MB; Stoll-Keller F; Baumert TF
    J Infect Dis; 2013 Apr; 207(8):1306-15. PubMed ID: 23335805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.
    Lavillette D; Morice Y; Germanidis G; Donot P; Soulier A; Pagkalos E; Sakellariou G; Intrator L; Bartosch B; Pawlotsky JM; Cosset FL
    J Virol; 2005 May; 79(10):6023-34. PubMed ID: 15857988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
    Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
    J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of neutralization antibodie induced by DNA vaccine of HCV envelope protein 2 in mice].
    Shao S; Zhou H; Tong Y; Ren Y; Chen Z
    Wei Sheng Yan Jiu; 2011 May; 40(3):295-8. PubMed ID: 21695897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins.
    Koutsoudakis G; Dragun J; Pérez-Del-Pulgar S; Coto-Llerena M; Mensa L; Crespo G; González P; Navasa M; Forns X
    PLoS One; 2012; 7(12):e52651. PubMed ID: 23300734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region.
    Alhammad Y; Gu J; Boo I; Harrison D; McCaffrey K; Vietheer PT; Edwards S; Quinn C; Coulibaly F; Poumbourios P; Drummer HE
    J Virol; 2015 Dec; 89(24):12245-61. PubMed ID: 26378182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus-neutralizing antibodies to hepatitis C virus.
    Wahid A; Dubuisson J
    J Viral Hepat; 2013 Jun; 20(6):369-76. PubMed ID: 23647953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus.
    Prentoe J; Serre SB; Ramirez S; Nicosia A; Gottwein JM; Bukh J
    J Virol; 2014 Feb; 88(3):1725-39. PubMed ID: 24257605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.